Affärsvärlden is keeping the medical technology company C-Rad’s stock in its portfolio, despite today’s weak interim report. This is stated in a comment on Thursday.
The stock is falling around 20 percent on the stock market today following a weak third-quarter report with poor order intake, lower sales and cancelled orders. The only bright spots were the gross margin and cost control, the newspaper assesses.
C-Rad is now launching a SEK 20 million share repurchase programme.
“The coming quarters will be important for C-Rad. The company must show that the weak order intake and performance in the third quarter were a temporary downturn rather than the beginning of a more prolonged decline. The order book adjustment has also damaged confidence,” writes Affärsvärlden.